Treatment rates for dangerously high cholesterol remains low
26 March 2018
Less than 40 per cent of people with severe elevations in cholesterol are being prescribed appropriate drug treatment, according to a nationally representative study reported in the American Heart Association's journal Circulation.
Data from the 1999-2014 National Health and Nutrition Examination Survey was used to estimate prevalence rates of self-reported screening, awareness and statin therapy among US adults age 20 and older with severely elevated LDL or "bad cholesterol" levels of 190 mg/dL or higher.
In addition, they considered a sub-group of patients with familial hypercholesterolemia, a genetic disorder that causes extreme elevations in cholesterol leading to an increased risk of early cardiovascular disease.
The frequency of cholesterol screening and awareness were high (at more than 80 per cent) among adults with definite / probable familial hypercholesterolemia and severely elevated cholesterol; however, use of cholesterol-lowering statins was low (38 per cent). Of those, only 30 per cent of patients with severely elevated cholesterol had been prescribed a high intensity statin.
The discrepancy between cholesterol screening and medical treatment was most pronounced in younger patients, uninsured patients and patients without a regular source of healthcare — such as a doctor's office or an outpatient clinic.
"Young adults may be less likely to think that they are at risk of cardiovascular disease, and clinicians may be less likely to initiate statin therapy in this population," wrote lead author Emily Bucholz, MD, PhD, MPH, Department of Medicine at Boston Children's Hospital in Massachusetts.
"It is possible that lifestyle modifications continue to be prescribed as an initial treatment prior to initiating statin therapy."
However, both the original 2002 National Cholesterol Education Program's Adult Treatment Panel III (ATP-III guidelines) and the current American College of Cardiology and American Heart Association cholesterol guidelines recommend initiation of statin therapy in patients with LDL cholesterol at or above 190 mg/dL.
"Markedly elevated levels of 'bad' cholesterol put you at increased risk of developing heart disease and developing it earlier in life," said Circulation Editor-in-Chief, Joseph A. Hill. "If your 'bad' cholesterol is over 190 you should work with your physician regarding optimal drug treatment, in addition to lifestyle changes and management of other risk factors."
Study authors said additional studies are needed to better understand how to close these gaps of screening and treatment.